Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report)’s share price reached a new 52-week low on Wednesday . The company traded as low as $6.10 and last traded at $6.15, with a volume of 6470 shares traded. The stock had previously closed at $7.15.
Wall Street Analyst Weigh In
Separately, Zacks Research upgraded shares of Oxford BioMedica to a “hold” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.
View Our Latest Stock Analysis on OXBDF
Oxford BioMedica Trading Down 5.2%
Oxford BioMedica Company Profile
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Further Reading
- Five stocks we like better than Oxford BioMedica
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
